证券代码：300725 证券简称：药石科技 公告编号：2025-070 特别提示： 年利率为 1.5%，且当期利息含税），扣税后的赎回价格以中国证券登记结算有 限责任公司深圳分公司（以下简称"中国结算"）核准的价格为准。 所"）摘牌。债券持有人持有的"药石转债"如存在被质押或被冻结的，建议在 停止转股日前解除质押或冻结，以免出现因无法转股而被赎回的情形。 适当性管理要求的，不能将所持"药石转债"转换为股票，特提请投资者关注不 能转股的风险。 石转债"，将按照 100.62 元/张的价格强制赎回，因目前"药石转债"二级市 场价格与赎回价格存在较大差异，特别提醒"药石转债"持有人注意在限期内 转股，如果投资者未及时转股，可能面临损失，敬请投资者注意投资风险。 自 2025 年 7 月 25 日至 2025 年 8 月 14 日期间，南京药石科技股份有限公司 （以下简称"公司"）股票已出现在任何连续三十个交易日中至少十五个交易日 的收盘价不低于药石转债当期转股价格的 130%（即 43.69 元/股）之情形，触发 《南京药石科技股份有限公司向不特定对象发行可转换公司债券并在创业板上 市募集说明书》（以下简称"《募集 ...

Group 1 - The core announcement from Yaoshi Technology indicates that the "Yaoshi Convertible Bonds" will be forcibly redeemed at a price of 100.62 CNY per bond if not converted by the market close on September 17, 2025 [2] - The current secondary market price of the "Yaoshi Convertible Bonds" is significantly different from the redemption price, which raises concerns for bondholders [2] - Investors are strongly advised to convert their bonds within the specified period to avoid potential losses [2]

Group 1 - The company Yaoshi Technology announced a mandatory redemption of its convertible bonds ("Yaoshi Convertible Bonds") at a price of 100.62 yuan per bond, effective after the market closes on September 17, 2025 [2] - The current market price of the "Yaoshi Convertible Bonds" is significantly different from the redemption price, prompting the company to remind bondholders to convert their bonds within the specified period to avoid potential losses [2]

Group 1 - The stock price of Yaoshi Technology as of August 14, 2025, closed at 47.70 yuan, down 0.15 yuan or 0.31% from the previous trading day [1] - The trading volume on that day was 175,953 hands, with a total transaction amount of 840 million yuan [1] - Yaoshi Technology focuses on the research and development of drug molecular building blocks, primarily serving the innovative drug development sector [1] Group 2 - On the evening of August 14, Yaoshi Technology announced that its fourth board of directors' ninth meeting approved the proposal for the early redemption of Yaoshi convertible bonds [1] - As of September 17, 2025, any unconverted "Yaoshi convertible bonds" will be forcibly redeemed at a price of 100.62 yuan per bond [1] - The company has reminded investors to convert their bonds within the specified period to avoid potential losses due to failure to convert in time [1]

Core Viewpoint - The article highlights the overdue status of commercial acceptance bills issued by the company, indicating potential liquidity issues and financial management concerns [1]. Group 1 - As of July 31, 2025, the total overdue balance of commercial acceptance bills amounts to 18.58 million yuan, with 1.80 million yuan already paid [1]. - The remaining unpaid overdue commercial acceptance bills total 16.78 million yuan [1]. Group 2 - The article provides a brief overview of various convertible bonds, including their redemption status and adjustments, indicating market activity and investor interest [2]. - Specific convertible bonds mentioned include Tian23, Huamao, Yaoshi, and others, with varying statuses on redemption and adjustments [2].

Core Viewpoint - The company, Yaoshi Technology, announced a plan for its shareholder, Nanjing Novicos Venture Capital Partnership, to reduce its holdings in the company, which may impact the stock price and investor sentiment [1]. Group 1: Shareholder Reduction Plan - Nanjing Novicos holds 5,404,744 shares, accounting for 2.7174% of the total share capital after excluding repurchased shares, and plans to reduce its entire stake within three months after the announcement [1]. - The reduction will occur through centralized bidding and block trading, with limits set at 1.00% and 2.00% of the total shares, respectively, over any consecutive 90-day period [1]. - Nanjing Novicos is an employee stock ownership platform established over ten years ago, aimed at binding core employees and promoting business development [1]. Group 2: Background Information - The shares to be reduced were issued before the company's initial public offering, including those transferred after the IPO [2]. - Yang Minmin, the company's controlling shareholder and chairman, is also the executive partner of Nanjing Novicos, making it an acting party of the company [3]. Group 3: Fundraising History - Over the past five years, the company has raised a total of 2.085 billion yuan, including 935 million yuan from a specific issuance in 2020 [5]. - The company issued 11.5 million convertible bonds in 2022, raising a total of 1.15 billion yuan, with net proceeds of approximately 1.143 billion yuan after deducting issuance costs [6].

Group 1 - The company, Nanjing Pharmablock Sciences Co., Ltd., issued convertible bonds to unspecified investors, with a total issuance of 11.5 million bonds at a face value of 100 RMB each, raising a total of 1.15 billion RMB [3][5][23] - The net proceeds from the bond issuance, after deducting various fees, amounted to approximately 1.14 billion RMB [3][23] - The bonds are set to mature in six years, with an annual interest rate that increases progressively from 0.3% in the first year to 2.0% in the sixth year [5][6] Group 2 - In 2024, the company reported a revenue of 1.688 billion RMB, a decrease of 2.12% year-on-year, while the net profit attributable to shareholders increased by 11.24% to 220 million RMB [21][22] - The company achieved a net cash flow from operating activities of 303 million RMB, reflecting a 22.68% increase compared to 2023 [21][22] - The company’s new orders in the CDMO segment grew by 12.43% year-on-year, with a 31.12% increase in order quantity [21][22] Group 3 - The initial conversion price for the bonds was set at 92.98 RMB per share, with subsequent adjustments based on stock performance and dividend distributions [8][29] - The bond's credit rating has been maintained at AA, with a stable outlook as per the annual tracking reports [18][26] - The company has implemented measures to manage customer credit and optimize cash flow, contributing to improved financial performance [21][22]